On September 28, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego (Press release, Veracyte, SEP 28, 2023, View Source [SID1234635506]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte’s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, including the Decipher Prostate test.
"Data that will be shared at this year’s ASTRO meeting will demonstrate the Decipher Prostate test’s ability to help clinicians make more informed treatment decisions based on the underlying biology of the individual patient’s prostate cancer and will reinforce that prostate cancer molecular tests are not all created equal nor are they interchangeable," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. "Our research collaborators will also present data derived from an analysis of the Decipher Genomics Research for Intelligent Discovery (GRID) database, which help advance understanding of the genomic mechanisms that drive treatment response."
Following are details of the six presentations, which will all take place at the San Diego Convention Center:
Date/Time:
Monday, October 2, 2023, 3:10-3:16 p.m. PT
Title:
Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer
Abstract #:
158 (oral presentation)
Presenter:
Ryan Phillips, M.D., Ph.D., The Mayo Clinic
Location:
Room 6 D/E
Date/Time:
Monday, October 2, 2023, 3:20-3:27 p.m. PT
Title:
Cross-Comparison Individual Patient Level Analysis of Three Gene Expression Signatures in Localized Prostate in over 50,000 Men
Abstract #:
159 (oral presentation)
Presenter:
Angela Jia, M.D., Ph.D., Case Western Reserve University
Location:
Room 6 D/E
Date/Time:
Sunday, October 1, 2023, 4:55-5:02 p.m.
Title:
A Precision Medicine Navigator Can Mitigate Inequities Associated with Utilization of Genomic Tests in Black Men with Prostate Cancer
Abstract #:
122 (oral presentation)
Presenter:
Alexander Allen, M.D., University of Maryland Medical Center
Location:
Room 4
Date/Time:
Monday, October 2, 2023, 5:00-6:00 p.m. PT
Title:
Longitudinal Profiling of Tumor RNA Expression Signatures Reveal Key Biological Features Associated with Response to Neoadjuvant Stereotactic Body Radiation Therapy in High-Risk Prostate Cancer
Abstract #:
2539 (poster)
Presenter:
Ariel Marciscano, M.D., Massachusetts General Hospital
Location:
Hall B2
Date/Time:
Tuesday, October 3, 2023, 2:30-3:45 p.m. PT
Title:
Predictive Value of Genomic Classifier Scores and Transcriptomic Data for Prostate Cancer Distant Metastasis Risk: A Multicenter Retrospective Study
Abstract #:
2926 (poster)
Presenter:
John Nikitas, M.D., University of California Los Angeles (UCLA) Radiation Oncology
Location:
Hall B2
Date/Time:
Tuesday, October 3, 2023, 2:30-3:45 p.m. PT
Title:
Dynamic Changes of Molecular Subtype Classification and Genomic Classifier Scores in High-Risk Prostate Cancer Patients Undergoing Pre-Operative Stereotactic Body Radiation Therapy
Abstract #:
2825 (poster)
Presenter
Marshall Diven, M.D., New York-Presbyterian Brooklyn Methodist Hospital
Location:
Hall B2